Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2007
Business Overview: Curis is a drug discovery and development company focused on leveraging biological signaling pathway technologies to create medicines primarily for cancer, as well as neurological, cardiovascular, and hair growth indications. The company operates in a single segment: developmental biology products. It relies heavily on strategic collaborations (e.g., Genentech, Wyeth, Procter & Gamble) for funding and commercialization, as it has no commercial products to date and has never been profitable.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Revenues | $2,362,786 | $2,038,430 |
| Net Loss | $(3,540,773) | $(4,048,994) |
| Loss Per Share (Basic & Diluted) | $(0.07) | $(0.08) |
| Cash and Cash Equivalents (End of Period) | $16,498,533 | $23,148,555 |
| Total Current Assets | $34,532,283 | $38,512,601 |
| Total Current Liabilities | $4,697,418 | $5,991,981 |
| Debt (Current Portion) | $1,243,516 | $1,246,289 |
| Debt (Long-Term) | $223,371 | $733,333 |
| Accumulated Deficit | $(692,424,268) | $(688,883,495) |
| Net Cash Used in Operating Activities | $(3,623,701) | $(873,278) |
Material Changes vs. Prior Period
- Revenue Composition: While Net Revenues increased by 16% to $2.36 million, the composition shifted significantly. Research and development contract revenue decreased by 50% to $1.28 million due to the conclusion of funding for the Hedgehog antagonist program with Genentech and the Spinal Muscular Atrophy Foundation program. Conversely, License fees increased by 271% to $1.08 million, driven by the accelerated amortization of the up-front license fee from the Genentech Wnt signaling pathway collaboration following the decision not to extend the research term.
- Contra-Revenues: Contra-revenues from co-development with Genentech dropped to zero in Q1 2007 compared to $826,100 in Q1 2006, as Curis ceased participation in co-development activities on August 31, 2006.
- Operating Expenses: Total costs and expenses decreased slightly by 2% to $6.25 million. Research and development expenses fell 5% to $3.30 million, while General and Administrative expenses rose 2% to $2.95 million, largely due to increased legal fees and stock-based compensation.
- Cash Flow: Net cash used in operating activities increased significantly to $3.62 million (from $0.87 million in the prior year), primarily due to the net loss and a decrease in deferred revenue of $1.26 million.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing capital resources ($32.74 million in cash, cash equivalents, and marketable securities) combined with contractually defined research funding (specifically from Wyeth through February 2008) will sustain operations into the fourth quarter of 2008. However, this excludes contingent milestone payments.
- Future Revenue: The company expects revenues from research and development contracts to continue declining in 2007 as funding ends on existing collaborations (except Wyeth). Future revenue is expected to rely on the amortization of previously received license fees and contingent milestone payments.
- Strategic Focus: Curis is reallocating resources to its internal "Targeted Cancer Drug Development Platform," specifically advancing the CUDC-101 candidate. The company is seeking new collaborators for this program but is not in advanced negotiations.
- Risks and Contingencies:
- Financing Needs: The company has an accumulated deficit of $692.4 million and expects to incur substantial losses. It will require additional financing, which may result in dilution.
- Collaboration Dependency: Revenue is heavily dependent on collaborators (Genentech, Wyeth, P&G). Termination or failure of these partners to meet milestones would materially impact operations.
- Subtenant Default: A subtenant at the 61 Moulton Street facility defaulted in 2006. While a settlement was reached in April 2007, collection of contingent payments remains uncertain.
- Restatement History: The company previously restated financial results for 2003-2005 due to accounting errors regarding revenue recognition, creating a risk of securities litigation.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $32.7 million cash position against the projected burn rate, considering the decline in research funding from collaborators.
- Genentech Collaboration Status: Confirm the finality of the Wnt signaling pathway agreement termination and the recognition of all remaining license fee revenue.
- Wyeth Funding Continuity: Assess the stability of the Wyeth collaboration, which is the primary remaining source of funded research personnel through early 2008.
- Internal Program Progress: Monitor the development status of the internal CUDC-101 candidate and the timeline for securing a new collaborator.
- Debt Covenants: Review compliance with the minimum working capital ratio covenant required by the Boston Private Bank & Trust Company loans.
- Subtenant Settlement: Track the collection of the remaining $187,000 and $106,000 contingent payments from the 61 Moulton Street subtenant settlement.